SCHEMBL22995643

SCHEMBL22995643

C=C(C)/C(C)=C/c1ccc(Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPA1 O75762 1/20 0.60
▸ CYP2C9 P11712 1/20 0.46
▸ HDAC3 O15379 1/20 0.44
▸ HDAC4 P56524 1/20 0.44
▸ HDAC1 Q13547 1/20 0.44
▸ HDAC7 Q8WUI4 1/20 0.44
▸ HDAC2 Q92769 1/20 0.44
▸ HDAC10 Q969S8 1/20 0.44
▸ HDAC11 Q96DB2 1/20 0.44
▸ HDAC8 Q9BY41 1/20 0.44
▸ HDAC6 Q9UBN7 1/20 0.44
▸ HDAC9 Q9UKV0 1/20 0.44
▸ HDAC5 Q9UQL6 1/20 0.44
▸ FBP1 P09467 1/20 0.41
▸ PTGS2 P35354 2/20 0.40
▸ HSD17B10 Q99714 1/20 0.39
▸ PTGS1 P23219 2/20 0.39
▸ AKR1C3 P42330 4/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ ALOX5 P09917 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14397175 0.80 ESR1 (0.54) PTGS2HSD17B10PTGS1CYP1A2ALDH1A1
SCHEMBL22995639 0.78 TRPA1 (0.60) TRPA1CYP2C9HDAC3HDAC4HDAC1
SCHEMBL3847992 0.77 TRPA1 (0.53) TRPA1CYP2C9HDAC3HDAC4HDAC1
SCHEMBL3847994 0.77 TRPA1 (0.53) TRPA1CYP2C9HDAC3HDAC4HDAC1
SCHEMBL11715588 0.77 TRPA1 (0.58) TRPA1CYP2C9HDAC3HDAC4HDAC1
SCHEMBL11715595 0.77 TRPA1 (0.58) TRPA1CYP2C9HDAC3HDAC4HDAC1
SCHEMBL122528 0.77 AKR1C3 (0.67) TRPA1CYP2C9HDAC3HDAC4HDAC1
SCHEMBL122529 0.77 AKR1C3 (0.67) TRPA1CYP2C9HDAC3HDAC4HDAC1
SCHEMBL9494242 0.77 TRPA1 (0.57) TRPA1CYP2C9HDAC3HDAC4HDAC1
Ap18 5 SCHEMBL1962033 0.75 TRPA1 (1.00) TRPA1CYP2C9HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021030335-A1 A STEREOISOMERICALLY PURE NK-3 RECEPTOR ANTAGONIST AND CRYSTALLINE FORMS THEREOF MILLENDO THERAPEUTICS, INC. (US) 2021-02-18 — — WO disclosed
Send feedback